245 related articles for article (PubMed ID: 12091355)
1. Soluble syndecan-1 promotes growth of myeloma tumors in vivo.
Yang Y; Yaccoby S; Liu W; Langford JK; Pumphrey CY; Theus A; Epstein J; Sanderson RD
Blood; 2002 Jul; 100(2):610-7. PubMed ID: 12091355
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation.
Dhodapkar MV; Abe E; Theus A; Lacy M; Langford JK; Barlogie B; Sanderson RD
Blood; 1998 Apr; 91(8):2679-88. PubMed ID: 9531576
[TBL] [Abstract][Full Text] [Related]
3. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma.
Derksen PW; Keehnen RM; Evers LM; van Oers MH; Spaargaren M; Pals ST
Blood; 2002 Feb; 99(4):1405-10. PubMed ID: 11830493
[TBL] [Abstract][Full Text] [Related]
4. Syndecan-1 in B lymphoid malignancies.
Sanderson RD; Børset M
Ann Hematol; 2002 Mar; 81(3):125-35. PubMed ID: 11904737
[TBL] [Abstract][Full Text] [Related]
5. Expression of syndecan-1 inhibits cell invasion into type I collagen.
Liebersbach BF; Sanderson RD
J Biol Chem; 1994 Aug; 269(31):20013-9. PubMed ID: 8051085
[TBL] [Abstract][Full Text] [Related]
6. Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment.
Dhodapkar MV; Sanderson RD
Leuk Lymphoma; 1999 Jun; 34(1-2):35-43. PubMed ID: 10350330
[TBL] [Abstract][Full Text] [Related]
7. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins.
Børset M; Hjertner O; Yaccoby S; Epstein J; Sanderson RD
Blood; 2000 Oct; 96(7):2528-36. PubMed ID: 11001907
[TBL] [Abstract][Full Text] [Related]
8. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
9. [The expression, secretion and regulation of membrane-soluble syndecan-1 in human multiple myeloma cells].
Li X; Lu Z; Klein B
Zhonghua Xue Ye Xue Za Zhi; 2000 Nov; 21(11):572-6. PubMed ID: 11225246
[TBL] [Abstract][Full Text] [Related]
10. Syndecan-1 mediates cell spreading in transfected human lymphoblastoid (Raji) cells.
Lebakken CS; Rapraeger AC
J Cell Biol; 1996 Mar; 132(6):1209-21. PubMed ID: 8601596
[TBL] [Abstract][Full Text] [Related]
11. Heparan sulfate-mediated cell aggregation. Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells.
Stanley MJ; Liebersbach BF; Liu W; Anhalt DJ; Sanderson RD
J Biol Chem; 1995 Mar; 270(10):5077-83. PubMed ID: 7890615
[TBL] [Abstract][Full Text] [Related]
12. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity.
Seidel C; Børset M; Hjertner O; Cao D; Abildgaard N; Hjorth-Hansen H; Sanderson RD; Waage A; Sundan A
Blood; 2000 Nov; 96(9):3139-46. PubMed ID: 11049995
[TBL] [Abstract][Full Text] [Related]
13. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen.
Ridley RC; Xiao H; Hata H; Woodliff J; Epstein J; Sanderson RD
Blood; 1993 Feb; 81(3):767-74. PubMed ID: 8427968
[TBL] [Abstract][Full Text] [Related]
14. Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions.
Liu W; Litwack ED; Stanley MJ; Langford JK; Lander AD; Sanderson RD
J Biol Chem; 1998 Aug; 273(35):22825-32. PubMed ID: 9712917
[TBL] [Abstract][Full Text] [Related]
15. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
Aref S; Goda T; El-Sherbiny M
Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
[TBL] [Abstract][Full Text] [Related]
16. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Yang Y; MacLeod V; Dai Y; Khotskaya-Sample Y; Shriver Z; Venkataraman G; Sasisekharan R; Naggi A; Torri G; Casu B; Vlodavsky I; Suva LJ; Epstein J; Yaccoby S; Shaughnessy JD; Barlogie B; Sanderson RD
Blood; 2007 Sep; 110(6):2041-8. PubMed ID: 17536013
[TBL] [Abstract][Full Text] [Related]
17. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
[TBL] [Abstract][Full Text] [Related]
18. Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9.
Kaushal GP; Xiong X; Athota AB; Rozypal TL; Sanderson RD; Kelly T
Br J Haematol; 1999 Feb; 104(2):365-73. PubMed ID: 10050721
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican.
Steinfeld R; Van Den Berghe H; David G
J Cell Biol; 1996 Apr; 133(2):405-16. PubMed ID: 8609172
[TBL] [Abstract][Full Text] [Related]
20. Inhibition by the soluble syndecan-1 ectodomains delays wound repair in mice overexpressing syndecan-1.
Elenius V; Götte M; Reizes O; Elenius K; Bernfield M
J Biol Chem; 2004 Oct; 279(40):41928-35. PubMed ID: 15220342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
